These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 31074329)

  • 1. Structural exploration of tetrahydroisoquinoline derivatives as HDAC8 inhibitors through multi-QSAR modeling study.
    Banerjee S; Adhikari N; Amin SA; Jha T
    J Biomol Struct Dyn; 2020 Mar; 38(5):1551-1564. PubMed ID: 31074329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview.
    Banerjee S; Adhikari N; Amin SA; Jha T
    Eur J Med Chem; 2019 Feb; 164():214-240. PubMed ID: 30594678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Essential elements regulating HDAC8 inhibition: a classification based structural analysis and enzyme-inhibitor interaction study of hydroxamate based HDAC8 inhibitors.
    Banerjee S; Amin SA; Adhikari N; Jha T
    J Biomol Struct Dyn; 2020 Nov; 38(18):5513-5525. PubMed ID: 31830865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative quantitative structural assessment of benzothiazine-derived HDAC8 inhibitors by predictive ligand-based drug designing approaches.
    Banerjee S; Baidya SK; Adhikari N; Jha T
    SAR QSAR Environ Res; 2022 Dec; 33(12):987-1011. PubMed ID: 36533308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diverse classes of HDAC8 inhibitors: in search of molecular fingerprints that regulate activity.
    Amin SA; Adhikari N; Jha T
    Future Med Chem; 2018 Jul; 10(13):1589-1602. PubMed ID: 29953251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. QSAR modeling to design selective histone deacetylase 8 (HDAC8) inhibitors.
    Cao GP; Thangapandian S; Son M; Kumar R; Choi YJ; Kim Y; Kwon YJ; Kim HH; Suh JK; Lee KW
    Arch Pharm Res; 2016 Oct; 39(10):1356-1369. PubMed ID: 27542119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docking and QSAR Studies of Aryl-valproic Acid Derivatives to Identify Antiproliferative Agents Targeting the HDAC8.
    Martínez-Pacheco H; Ramírez-Galicia G; Vergara-Arias M; Gertsch J; Fragoso-Vazquez JM; Mendez-Luna D; Abujamra AL; Cristina CL; Cecilia RM; Mendoza-Lujambio I; Correa-Basurto J
    Anticancer Agents Med Chem; 2017; 17(7):927-940. PubMed ID: 27774878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An insight into selective and potent inhibition of histone deacetylase 8 through induced-fit docking, pharmacophore modeling and QSAR studies.
    Kashyap K; Kakkar R
    J Biomol Struct Dyn; 2020 Jan; 38(1):48-65. PubMed ID: 30633630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel potential selective HDAC8 inhibitors by combine ligand-based, structure-based virtual screening and in-vitro biological evaluation.
    Debnath S; Debnath T; Bhaumik S; Majumdar S; Kalle AM; Aparna V
    Sci Rep; 2019 Nov; 9(1):17174. PubMed ID: 31748509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities.
    Zhang Y; Feng J; Jia Y; Wang X; Zhang L; Liu C; Fang H; Xu W
    J Med Chem; 2011 Apr; 54(8):2823-38. PubMed ID: 21476600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-activity relationships of HDAC8 inhibitors: Non-hydroxamates as anticancer agents.
    Amin SA; Adhikari N; Jha T
    Pharmacol Res; 2018 May; 131():128-142. PubMed ID: 29514055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Designing potential HDAC3 inhibitors to improve memory and learning.
    Amin SA; Adhikari N; Jha T; Ghosh B
    J Biomol Struct Dyn; 2019 May; 37(8):2133-2142. PubMed ID: 30044204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HDAC8 as an emerging target in drug discovery with special emphasis on medicinal chemistry.
    Rajaraman S; Balakrishnan R; Deshmukh D; Ganorkar A; Biswas S; Pulya S; Ghosh B
    Future Med Chem; 2023 May; 15(10):885-908. PubMed ID: 37227732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, biological evaluation and molecular docking study of arylcarboxamido piperidine and piperazine-based hydroxamates as potential HDAC8 inhibitors with promising anticancer activity.
    Trivedi P; Adhikari N; Amin SA; Bobde Y; Ganesh R; Jha T; Ghosh B
    Eur J Pharm Sci; 2019 Oct; 138():105046. PubMed ID: 31421254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitors.
    Suzuki T; Muto N; Bando M; Itoh Y; Masaki A; Ri M; Ota Y; Nakagawa H; Iida S; Shirahige K; Miyata N
    ChemMedChem; 2014 Mar; 9(3):657-64. PubMed ID: 24403121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanistic Exploration of Methionine 274 Acting as a "Switch" of the Selective Pocket Involved in HDAC8 Inhibition: An in Silico Study.
    Yao P; Gao Q; Wang Y; Yao Q; Zhang J
    ChemMedChem; 2021 Jun; 16(12):1933-1944. PubMed ID: 33686739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Therapeutic Perspective of HDAC8 in Different Diseases: An Overview of Selective Inhibitors.
    Fontana A; Cursaro I; Carullo G; Gemma S; Butini S; Campiani G
    Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of Histone Deacetylase 8 (HDAC8) Selective Inhibition Reveals Specific Active Site Structural and Functional Determinants.
    Marek M; Shaik TB; Heimburg T; Chakrabarti A; Lancelot J; Ramos-Morales E; Da Veiga C; Kalinin D; Melesina J; Robaa D; Schmidtkunz K; Suzuki T; Holl R; Ennifar E; Pierce RJ; Jung M; Sippl W; Romier C
    J Med Chem; 2018 Nov; 61(22):10000-10016. PubMed ID: 30347148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and Investigation of Therapeutic Potential of Isoform-Specific HDAC8 Inhibitors for the Treatment of Cutaneous T Cell Lymphoma.
    Umamaheswari A; Puratchikody A; Hari N
    Anticancer Agents Med Chem; 2019; 19(7):916-934. PubMed ID: 30836926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design of Potent Panobinostat Histone Deacetylase Inhibitor Derivatives: Molecular Considerations for Enhanced Isozyme Selectivity between HDAC2 and HDAC8.
    Stoddard SV; May XA; Rivas F; Dodson K; Vijayan S; Adhika S; Parker K; Watkins DL
    Mol Inform; 2019 Mar; 38(3):e1800080. PubMed ID: 30369061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.